TradingView
MarketMoversReport
Apr 6, 2022 5:42 PM
BioXcel Therapeutics Announces FDA Approval of IGALMI
Long
NASDAQ:BTAI
1D
BioXcel Therapeutics, Inc.
NASDAQ
Description
⋅
Apr 6, 2022 5:42 PM
BTAI: BioXcel Therapeutics
2022-04-06 07:00:00
BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
Beyond Technical Analysis
More